On July 27, 2026, the Hong Kong stock market showed a volatile pattern overall, with the Hang Seng Index edging down 0.12% to close at 19,875 points. However, the bio-pharma sector bucked the trend and became the biggest highlight of the day. The Hang Seng Healthcare Index rose 2.3% throughout the day, with several biotech stocks gaining over 5%. Among them, BeiGene (06160.HK) rose 6.8%, Innovent Biologics (01801.HK) rose 5.4%, and Akeso (09926.HK) rose 4.9%. Market analysts pointed out that the strong sector performance was mainly driven by three factors: the NMPA's new policy to accelerate approval for innovative drugs, positive mid-term earnings forecasts from multiple companies, and significant increase in Southbound capital positions.
Policy Dividend: Innovative Drug Approval Further Accelerated
On the evening of July 26, the National Medical Products Administration (NMPA) released "Several Measures to Further Accelerate the Approval of Innovative Drugs for Market Launch," specifying priority review and approval for breakthrough therapies, rare disease drugs, and pediatric drugs, and shortening the default review period for clinical trial applications from 60 working days to 40 working days. This policy is regarded by the industry as another major positive following the 2024 "Implementation Plan for Whole-Chain Support of Innovative Drug Development." Li Lin, pharmaceutical industry analyst at CICC, said: "This acceleration directly shortens the time window from R&D to market for innovative drugs, providing substantive benefits to Hong Kong-listed biotech companies, especially those with heavy pipeline products in late clinical stages."
Earnings Catalysts: Strong Mid-Term Forecasts from Multiple Companies
Entering late July, Hong Kong-listed bio-pharma companies have been releasing mid-term earnings forecasts. BeiGene expects a 45% year-on-year increase in revenue for the first half of 2026, with global sales of its core product Zanubrutinib exceeding RMB 5 billion, mainly due to increased penetration in the US and European markets. Innovent Biologics forecasted a net profit turnaround in the first half, with its PD-1 inhibitor Sintilimab adding two new indications included in medical insurance, leading to significant volume expansion. Akeso's bispecific antibody AK112 (Ivonescimab) achieved positive data in first-line treatment of non-small cell lung cancer, driving doubling of product sales revenue. Positive earnings expectations boosted investor confidence, leading to active capital inflows.
Capital Flows: Southbound Capital Net Buys Innovative Drug Sector
According to Hong Kong Exchange data, Southbound capital net bought approximately HK$3.8 billion in Hong Kong stocks on July 27, with the bio-pharma sector receiving net purchases of HK$1.26 billion, ranking first among all industries. Specifically, BeiGene, Innovent, and WuXi Biologics (02269.HK) received net purchases of HK$320 million, HK$280 million, and HK$210 million, respectively. Industry insiders pointed out that with relatively high valuations in the A-share pharmaceutical sector, Hong Kong-listed pharmaceutical stocks offer better value and improving liquidity, attracting mainland capital to allocate southbound.
Industry Outlook: R&D Innovation and Commercialization Advancing Together
Looking ahead to the second half of the year, multiple institutions believe the Hong Kong bio-pharma sector still has structural opportunities. A research report from Guotai Junan International pointed out that with rising expectations of Fed rate cuts, the global bio-pharma financing environment is expected to improve, expanding funding channels for Hong Kong-listed biotech companies. Meanwhile, domestic medical insurance negotiation rules are stabilizing, and the volume expansion path after innovative drugs are included in the insurance is clear. Recommended companies include those with global clinical capabilities and differentiated product pipelines, such as BeiGene, Akeso, and RemeGen (09995.HK). In addition, the CXO sector benefits from the rebound in global new drug R&D outsourcing demand, and leading companies like WuXi AppTec (02359.HK) and Pharmaron (03759.HK) are also worth tracking.
Risk Warnings
Although the sector has shown strong short-term performance, investors still need to watch for risks: first, uncertainty in Fed monetary policy may cause fluctuations in global capital flows; second, failure of innovative drug clinical trials or delays in market approval; third, medical insurance price cuts exceeding expectations affecting corporate profitability. It is recommended to control positions, diversify investments, and allocate high-quality targets with a long-term perspective.